NL-OMON39783已完成2 期
A randomised, controlled, double-blind trial to investigate the effects of a new infant formula on growth, tolerance and safety in healthy term infants. - Mercurius
utricia Research - Centre for Specialised Nutrition0 个研究点目标入组 121 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 121
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11(—)
入选标准
- •Healthy term infants (gestational age >= 37 1/7 and <= 42 6/7 weeks) - Age <= 35 days (preferably as soon as possible after birth) - Birth weight within normal range for gestational age and sex (10th to 90th percentile according to local applicable growth charts) - Infants who are exclusively formula fed (mothers who have chosen not to breastfeed or mothers who ended breastfeeding by time of inclusion) or - Infants who are exclusively breastfed and whose mothers are willing to exclusively breastfeed at least till their infant is 13 weeks of age (and preferably till 17 weeks of age).
- •For the sub-study:
- •Once 176 infants receiving study product have been included in the main study, inclusion in the sub-study will start. The inclusion criterium **Age <= 35 days (preferably as soon as possible after birth)** will no longer be valid and be replaced by: **Age <= 14 days (preferably as soon as possible after birth)**.
排除标准
- •- Infants known to have current or previous illnesses/conditions or intervention which could interfere with the study or its outcome parameters, such as gastrointestinal malformations, congenital metabolic disorders, immune deficiency or major surgery, as per investigator*s clinical judgement - Infants whose mother is known to suffer from hepatitis B or human immunodeficiency virus (HIV)
研究者
相似试验
已完成
3 期
A randomised, double-blind, controlled, parallel-group, multi-country study to investigate the effect of a partially hydrolysed infant formula with added synbiotics on gut microbiota composition and clinical effectiveness in infants at high risk of developing allergy.infants at high risk of developing allergy10001708NL-OMON50109utricia44
已完成
2 期
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis PatientsPulmonary alveolar proteinosisNL-OMON46238Savara ApS9
已完成
2 期
A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysmAbdominal aortic aneurysmdilation of the aorta in the abdomen10002363NL-OMON38947ovartis7
已完成
2 期
A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer*s DiseaseAlzheimer's diseasedementianeurodegenerative disease10012272NL-OMON54863Cortexyme, Inc.31
已完成
不适用
A randomized, double-blind, placebo-controlled study to investigate the effects of an 8-week recombinant human erythropoietin (NeoRecormon) treatment on well-trained cyclists and their cycling performance.FietsprestatieCycling performanceslow cyclingNL-OMON44014Centre for Human Drug Research48
